P/B
3,9
Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
$177.5M
Market Cap • 10/8/2026
2006
(20 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
3,9
P/EBITDA
1,4
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,6
EPS
—
Market Cap
Market Cap
177,5M
EV
118M
EV/Revenue
2,6
EV/EBITDA
0,9
EV/EBIT
0,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-45%
Total Yield
-45%
Payout
0%
Retained Earnings
-579,3M
Profitability
Gross Margin
100%
EBITDA Margin
283,5%
EBIT Margin
280,7%
Net Margin
242,5%
D&A/EBITDA
0%
R&D/Revenue
-118,3%
Capex/Revenue
0,1%
Capex/D&A
3%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
4,8%
% Goodwill
0%
ROE
275,4%
ROIC
332,6%
Growth
CAGR Revenue 5Y
-15%
CAGR Op. Income 5Y
-12,7%
CAGR Net Income 5Y
-15,2%
CAGR EPS 5Y
-38,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
12,8
Quick Ratio
12,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!